192 related articles for article (PubMed ID: 27490418)
1. Wound Healing Complications in Kidney Transplant Recipients Receiving Everolimus.
Ueno P; Felipe C; Ferreira A; Cristelli M; Viana L; Mansur J; Basso G; Hannun P; Aguiar W; Tedesco Silva H; Medina-Pestana J
Transplantation; 2017 Apr; 101(4):844-850. PubMed ID: 27490418
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses.
Miranda TA; Felipe CR; Santos RHN; Medina Pestana JO; Tedesco-Silva Junior H
Ther Drug Monit; 2020 Dec; 42(6):811-820. PubMed ID: 32657909
[TBL] [Abstract][Full Text] [Related]
3. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J
Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172
[TBL] [Abstract][Full Text] [Related]
4. Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses.
Tedesco-Silva H; Felipe C; Ferreira A; Cristelli M; Oliveira N; Sandes-Freitas T; Aguiar W; Campos E; Gerbase-DeLima M; Franco M; Medina-Pestana J
Am J Transplant; 2015 Oct; 15(10):2655-64. PubMed ID: 25988935
[TBL] [Abstract][Full Text] [Related]
5. The effect of anti-thymocyte globulin and everolimus on the kinetics of cytomegalovirus viral load in seropositive kidney transplant recipients without prophylaxis.
Basso G; Felipe CR; Cristelli MP; Mansur Siliano J; Viana L; Ferreira Brigido AN; Stopa Martins SB; de Castro Lima Santos DW; Aguiar WF; Tedesco-Silva Junior H; Medina-Pestana JO
Transpl Infect Dis; 2018 Aug; 20(4):e12919. PubMed ID: 29797676
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness Analysis of Everolimus versus Mycophenolate in Kidney Transplant Recipients Receiving No Pharmacological Prophylaxis for Cytomegalovirus Infection: A Short-Term Pharmacoeconomic Evaluation (12 Months).
Felipe C; Tedesco-Silva H; Ferreira Brigido A; Bessa A; Ruppel P; Hiramoto L; de Paula M; Cristelli M; Stopa S; Mansur J; Viana L; Fahham L; Pepe C; Medina-Pestana J
Value Health Reg Issues; 2017 Dec; 14():108-115. PubMed ID: 29254534
[TBL] [Abstract][Full Text] [Related]
7. Wound healing adverse events in kidney transplant recipients receiving everolimus with reduced calcineurin inhibitor exposure or current standard-of-care: insights from the 24-month TRANSFORM study.
Citterio F; Henry M; Kim DY; Kim MS; Han DJ; Kenmochi T; Mor E; Tisone G; Bernhardt P; Hernandez Gutierrez MP; Watarai Y
Expert Opin Drug Saf; 2020 Oct; 19(10):1339-1348. PubMed ID: 32633157
[TBL] [Abstract][Full Text] [Related]
8. Long-term Efficacy and Safety of Everolimus Versus Mycophenolate in Kidney Transplant Recipients Receiving Tacrolimus.
Nunes Ficher K; Dreige Y; Gessolo Lins PR; Nicolau Ferreira A; Toniato de Rezende Freschi J; Linhares K; Stopa Martins S; Custodio L; Cristelli M; Viana L; Wagner Santos D; de Marco R; Gerbase-DeLima M; Proença H; Aguiar W; Nakamura M; Rosso Felipe C; Medina Pestana J; Tedesco Silva H
Transplantation; 2022 Feb; 106(2):381-390. PubMed ID: 33988338
[TBL] [Abstract][Full Text] [Related]
9. Prospective randomized study comparing everolimus and mycophenolate sodium in de novo kidney transplant recipients from expanded criteria deceased donor.
Ferreira AN; Felipe CR; Cristelli M; Viana L; Mansur J; de Paula M; Wagner D; de Marco R; Gerbase-DeLima M; Proença H; Aguiar W; Medina-Pestana J; Tedesco-Silva Junior H
Transpl Int; 2019 Nov; 32(11):1127-1143. PubMed ID: 31278785
[TBL] [Abstract][Full Text] [Related]
10. A Head-to-head Comparison of De Novo Sirolimus or Everolimus Plus Reduced-dose Tacrolimus in Kidney Transplant Recipients: A Prospective and Randomized Trial.
Toniato de Rezende Freschi J; Cristelli MP; Viana LA; Ficher KN; Nakamura MR; Proença H; Dreige YC; de Marco R; de Lima MG; Foresto RD; Aguiar WF; Medina-Pestana J; Tedesco-Silva H
Transplantation; 2024 Jan; 108(1):261-275. PubMed ID: 37525373
[TBL] [Abstract][Full Text] [Related]
11. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J
Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Elective Conversion From Sotrastaurin (STN) to Tacrolimus (TAC) or Mycophenolate (MPS) in Stable Kidney Transplant Recipients.
Hannun P; Felipe C; Ferreira A; Sandes-Freitas T; Cristelli M; Aguiar W; Franco M; Campos E; Gerbase de Lima M; Tedesco-Silva H; Medina-Pestana J
Ther Drug Monit; 2016 Jun; 38(3):293-9. PubMed ID: 26919549
[TBL] [Abstract][Full Text] [Related]
13. Quadruple immunosuppression with basiliximab, tacrolimus, mycophenolate mofetil and prednisone is safe and effective for renal transplantation.
Miura M; Harada H; Fukuzawa N; Iwami D; Taniguchi A; Seki T; Togashi M; Ogawa Y; Satoh H; Hirano T
Clin Transplant; 2005; 19 Suppl 14():54-8. PubMed ID: 15955170
[TBL] [Abstract][Full Text] [Related]
14. Chronopharmacokinetics of mycophenolic acid and its glucuronide and acyl glucuronide metabolites in kidney transplant recipients converted from cyclosporine to everolimus.
Tedesco-Silva H; Felipe CR; Slade A; Schmouder RL; Medina Pestana JO
Ther Drug Monit; 2012 Dec; 34(6):652-9. PubMed ID: 23131696
[TBL] [Abstract][Full Text] [Related]
15. Induction treatment with rabbit antithymocyte globulin versus basiliximab in renal transplant recipients with planned early steroid withdrawal.
Martin ST; Roberts KL; Malek SK; Tullius SG; Vadivel N; De Serres S; Grafals M; Elsanjak A; Filkins BA; Chandraker A; Gabardi S
Pharmacotherapy; 2011 Jun; 31(6):566-73. PubMed ID: 21923440
[TBL] [Abstract][Full Text] [Related]
16. The impact of everolimus in reducing cytomegalovirus events in kidney transplant recipients on steroid-avoidance strategy: 3-year follow-up of a randomized clinical trial.
de Sandes-Freitas TV; Pinheiro PMA; Sales MLMBO; Girão CM; Campos ÉF; Esmeraldo RM
Transpl Int; 2018 Dec; 31(12):1345-1356. PubMed ID: 29969826
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine.
Felipe CR; Oliveira NI; Hannun PG; de Paula MI; Tedesco-Silva H; Medina-Pestana JO
Ther Drug Monit; 2016 Feb; 38(1):64-72. PubMed ID: 26274696
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppressive therapy for kidney transplantation in children and adolescents: systematic review and economic evaluation.
Haasova M; Snowsill T; Jones-Hughes T; Crathorne L; Cooper C; Varley-Campbell J; Mujica-Mota R; Coelho H; Huxley N; Lowe J; Dudley J; Marks S; Hyde C; Bond M; Anderson R
Health Technol Assess; 2016 Aug; 20(61):1-324. PubMed ID: 27557331
[TBL] [Abstract][Full Text] [Related]
19. Lipid profile changes during the first year after kidney transplantation: risk factors and influence of the immunosuppressive drug regimen.
Spinelli GA; Felipe CR; Park SI; Mandia-Sampaio EL; Tedesco-Silva H; Medina-Pestana JO
Transplant Proc; 2011 Dec; 43(10):3730-7. PubMed ID: 22172836
[TBL] [Abstract][Full Text] [Related]
20. Pilot Randomized Trial of Tacrolimus/Everolimus vs Tacrolimus/Enteric-Coated Mycophenolate Sodium in Adult, Primary Kidney Transplant Recipients at a Single Center.
Ciancio G; Tryphonopoulos P; Gaynor JJ; Guerra G; Sageshima J; Roth D; Chen L; Kupin W; Mattiazzi A; Tueros L; Flores S; Hanson L; Powell RH; Ruiz P; Vianna R; Burke GW
Transplant Proc; 2016; 48(6):2006-10. PubMed ID: 27569936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
